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Summary Forty-six patients with previously untreated, advanced ovarian cancer received carboplatin (JM8,
CBDCA) and chlorambucil (CLB) to assess the efficacy and toxicity of this combination. Carboplatin
300mgm-2 was given on day 1 with CLB 10mg daily for 7, 10 or 14 days; 6 treatment courses were given at
4-6 weekly intervals in the absence of disease progression.
Tumour response was assessed, where possible, by restaging laparotomy after 6 treatment cycles. Five
complete and 16 partial remission were seen in 37 evaluable patients giving an overall response rate of 57%.
The median survival of all patients was 15 months.
The major toxicity was myelosuppression. Nausea and vomiting were generally minor (WHO, grades I or
II) and most courses were given on an outpatient basis. Leucopenia was the major factor causing treatment
delays, particularly with the 10 and 14 day CLB regimens. Thrombocytopenia was minimal in the early
chemotherapy cycles but the data suggest that cumulative toxicity may occur. This combination may provide
a satisfactory degree of efficacy with less toxicity than cisplatin-based regimens.
Since the activity of cisplatin in ovarian carcinoma was
documented (Wiltshaw & Carr, 1974) it has become the
mainstay of most chemotherapeutic regimens (Sessa, 1986).
Controversy remains as to whether platinum-based com-
binations are superior to cisplatin alone. The only ran-
domised trial to address this question showed a higher
response rate forthe combination arms (Gruppo Interegion-are
Cooperativo Oncologico Ginecologia, 1987) though the dose
of single agent cisplatin (50mgm-2) may have been sub-
optimal in view of the demonstrable dose/response effect in
previously treated patients (Ozols et al., 1985). Nevertheless
combination schedules which incorporate cisplatin have
become standard in many centres. However, cisplatin-
induced nausea, vomiting and malaise are often difficult to
control and may cause marked morbidity (Wiltshaw & Carr,
1974). Cumulative renal impairment and peripheral neuro-
pathy occur with significant frequency (Wiltshaw et al.,
1986). These side effects have raised the question whether it
is justifiable to treat the majority of women with advanced
ovarian cancer with cisplatin-containing regimens (Williams
et al., 1985).
Experience with the platinum analogues has shown that
much of this toxicity may be significantly reduced, but
myelosuppression is dose limiting (Evans et al., 1983;
Bramwell et al., 1985). In a randomised trial, carboplatin
(JM8, CBDCA) as a single agent was as effective as the
parent drug in untreated patients with advanced ovarian
cancer, but was clearly much better tolerated (Wiltshaw et
al., 1985).
Combinations of carboplatin with alkylating agents are
currently being tested. Since increased myelosuppression is
inevitable, dose reductions of carboplatin are required, this is
rarely necessary when cisplatin is used in combination. It
remains to be seen whether such alkylating agent/carboplatin
combinations are more effective than carboplatin alone as
was seen for the parent drug. This question can only be
addressed in a randomised trial, and so this pilot study
combining chlorambucil with carboplatin was initiated.
Chlorambucil (CLB) was selected on the basis of minimal
toxicity as there is no evidence that one particular alkylating
agent is more active than any other in ovarian cancer
(Young et al., 1974). CLB avoids the potential cystitis of
oral cyclophosphamide and the gastrointestinal toxicity and
alopecia of intravenous cyclophosphamide or ifosfamide.
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The study was designed to determine the dose of CLB which
could be safely combined with 300mgm 2 carboplatin.
Patients and methods
Entry into the study was precluded by prior therapy or renal
impairment (creatinine clearance <50ml min-1). Forty-six
patients were entered following an initial diagnosis of
advanced epithelial ovarian cancer. Though one patient was
shown to have a soft tissue sarcoma on pathology review,
she is evaluable for toxicity. Characteristics of the other
patients are shown in Table I.
Treatment comprised carboplatin 300mgm 2 as an i.v.
infusion in 250ml of 5% dextrose over 30min on day 1.
Patients received oral chlorambucil 10mgday-1 for 7, 10 or
14 days on a non-randomised basis. Initially 6 patients were
entered at each CLB dose level, but, as the study progressed,
all patients were treated on the 7 day schedule. Full blood
counts were measured at weekly intervals and in the initial
phase of the study subsequent treatment courses were given
on day 28 if the WBC >4.0 x 1091 -1, and platelets
> 100 x 1091-1. In the later phase of the trial, the threshold
WBC for retreatment was reduced to 3.0 x 1091-1.
Measurable tumour was not a requirement but, where
possible, response was evaluated by a second look laparo-
tomy on completion of 6 treatment courses. Complete
response (CR) was defined as macroscopic regression of
previously documented disease with no evidence of tumour
in resected pelvic organs, omentum, random peritoneal biop-
sies or peritoneal washings. Partial response (PR) was
recorded for >50% reduction in tumour volume or micro-
scopic residual disease in resected specimens. Stable disease
(SD) comprised a <50% reduction and/or a <25% increase
in pretreatment tumour volume: progressive disease was a
>25% increase in tumour volume or the appearance of
tumour at new sites.
Results
Toxicity
As anticipated, myelosuppression was the major toxicity.
Some degree of leucopenia followed the majority of treat-
ment cycles though significant thrombocytopenia was rarely
seen until later courses. A falling WBC between days 28 and
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Table I Patient characteristics
Forty-five patients entered March 1985 - March 1986 with epithelial ovarian
carcinoma, age 24-71 years, median 59 years.
Stage II n =2
III n=36 No residual disease n=1
IV n=7
Primary surgery
Minimal residual disease (<2cm) n=12
Moderate residual disease (2-5 cm) n = 12
Bulk residual disease (>5cm) n = 11
Liver 6
Lung 1
TAH+BSO+omentectomy+bowel resection
TAH+BSO+omentectomy
TAH+BSO
Oophorectomy +/ omentectomy
Biopsy
16
16
7
Performance status >80 n= 19
60-80 n=26
Table II Myelosuppression of carboplatin/CLB
WBC
Nadir
median
n (range)
Course I
CLB
7 Days
CLB
10 Days
CLB
14 Days
Day 28
median
(range)
Day 42
median
(range)
Platelet
nadir
median
(range)
29 3.5 4.4 4.9 125
(1.5-8.1) (1.5-10.1) (2.9-8.8) (62-378)
6 3.5
(2.0-6.6)
11 3.5
(1.8-5.3)
n Nadir
Course II
CLB
7 Days
CLB
10 Days
CLB
14 Days
42 was noted
29 2.9
(1.3-5.9)
6 2.0
(1.3-2.3)
4.1
(2.7-7.9)
3.8
(3.2-9.8)
WBC
3.1
(2.8-3.9)
3.5
(1.8-4.7)
165
(87-198)
160
(85-390)
Platelet
Day 28 Day 42 nadir
3.9
(2.0-7.0)
3.7
(2.8-4.8)
2.7 118
(2.4-4.5) (40-249)
124
(90-129)
9 2.7 3.1 4.1 110
(1.5-3.3) (2.3-4.3) (3.3-4.7) (61-259)
in some patients not retreated on day 28
because of grade I leucopenia, indicating prolonged myelo-
toxicity often with a dual nadir occurring between days 21-
28 and 35-42.
Nadir WBC and platelet counts for the initial two treat-
ment cycles are shown in Table II. There was no correlation
between the degree of myelosuppression and CLB dosage
though this may have influenced the duration of leucopenia.
The initial study design, with a retreatment WBC
>4.0x 1091-1 was responsible for significant treatment
delays (>14 days) in 20 of 36 patients completing 3
treatment courses. These included 9 of 19 patients receiving
CLB for 7 days, 5 of 6 treated for 10 days and 6 of 11
receiving 14 day CLB (the other 5 patients on the 14 day
schedule were withdrawn from study for other reasons; 3
disease progression, 1 early death and 1 renal failure).
Patients retreated on day 42 with grade I leucopenia received
either 5 or 7 days CLB. Carboplatin dosage was reduced to
250mgm-2 for 2 or more cycles in 8 patients due to day 42
grade II leucopenia despite CLB dose reduction.
As, however, it seemed possible to continue combination
chemotherapy on a pretreatment WBC between 3.0 and
4.0 x 1091 1 without cumulative leucopenia, the study was
modified to minimise treatment delay. The final 10 patients
were entered on the 7 day CLB schedule and retreated on
day 28 if the WBC exceeded 3.Ox l091-1. Two of 10
patients were withdrawn, for tumour progression, and five
completed 6 cycles as planned at 4 weekly intervals. The
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Figure 1 Proportion of patients receiving the 7 day chloram-
bucil combination with WHO Grade haematological toxicity in
each treatment course.
remaining 3 patients each had a single treatment delay
during the 6 courses which were given without dosage
modification.
Nadir WBC and platelet counts in patients receiving
carboplatin with 7 day CLB are shown in Figure 1. Five of
these 29 patients had significant dose reductions for myelo-
suppression and a further 2 were withdrawn from study due
to prolonged leucopenia. Thrombocytopenia was less marked
than leucopenia in the early treatment courses, though
Figure 1 suggests that bone marrow toxicity may well be
cumulative. There was no correlation between nadir WBC
and renal function as measured by creatinine clearance.
Three patients received oral antibiotics as outpatients for
clinical infection. No patient had evidence of spontaneous or
tumour related haemorrhage associated with thrombocyto-
penia. Red cell transfusions were required by 5 patients
whose Hb fell to <8gdl-' during treatment, in 2 of these
tumour progression was evident.
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Figure 2 Proportion of patients with gastrointestinal toxicity resulting from each treatment course.
Table III Response to chemotherapy
9 patients are inevaluable for response:
3 without residual disease after primary surgery
1 without clinically assessible disease not surgically re-evaluated in view of age
1 early death at 4 weeks
3 withdrawn: 2 myelosuppression continued on CLB alone
1 renal failure
1 pathology review: soft tissue sarcoma
37 evaluable patients:
5 CR (14%): confirmed by laparotomy (4) and laparoscopy (1)
16 PR (43%): 11 surgically evaluated: 4 macroscopic CR, pathological CR
2 macroscopic residual disease resected
5 macroscopic residual disease unresectable
5 clinical PR
6 SD: 4 surgically restaged, of these 3 were 'clinical PR'
10 PD
Overall response rate: 57%
Table IV Tumour response (epithelial ovarian cancer)
residual disease prior to chemotherapy
in relation to
CR PR SD PD Non-evaluable
Residual disease n
None 3 3
<2cm 12 3 3 1 2 3
2-5cm 12 1 5 2 3 1
>5cm 11 6 2 2 1
Stage IV 7 1 2 1 3
Total 45 5 16 6 10 8
Non-haematological toxicity
Treatment was well tolerated by most patients; the majority
of courses were administered on an outpatient basis. Some
degree of nausea or vomiting (Figure 2) was experienced by
the majority, despite prophylactic metoclopramide (high dose
11%, standard dose 23% courses), a nabilone/prochlor-
perazine combination (42% courses), prochlorperazine alone
(10% courses) or lorazepam/chlorpromazine (13% courses).
The duration of vomiting rarely exceeded 12h and most
patients had recovered from nausea by 48 h. One patient
developed transient diarrhoea in association with the 5th and
6th carboplatin infusions which was assumed to be drug
related.
Renal failure occurred in a single patient during the first
cycle. Her creatinine clearance was 78 mlmin- 1 pretreatment
and 23mlmin-i on day 28 without evidence of obstructive
uropathy or proteinuria. Therapy continued with CLB alone
and renal function recovered spontaneously. In retrospect
this was attributed to concomitant therapy with mefanamic
acid (Adams et al., 1986). Overall 10 of 46 patients received
non-steroidal anti-inflammatory drugs at some time during
the study (8 mefanamic acid: 2 others) but renal impairment
was not seen in the other 9.
Mild alopecia occurred in 3 patients (2 grade I, 1 grade
II). One patient experienced transient tinnitus during ther-
apy, without any significant hearing loss on audiometry.
Another patient developed lower motor neurone weakness
affecting both legs following a combined epidural/general
anaesthetic for restaging laparotomy and tumour debulking
after 6 treatment cycles. The relative contributions of
regional anaesthesia and carboplatin to this complication are
unclear. Symptomatic neuropathy did not occur in any of
the other 44 patients.
Response
Nine patients are inevaluable for response for reasons noted
in Table III. The patient not surgically re-evaluated on
grounds of age relapsed with malignant ascites 3 months
after chemotherapy was discontinued. The other 3 patients
with no residual tumour at the start of treatment remain
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clinically disease free 6, 9 and 18 months from completion of
6 cycles. Interestingly, the patient with a soft tissue sarcoma
experienced marked symptomatic improvement without
objective evidence of tumour response.
Response evaluation for all other patients is shown in
Table III. The chlorambucil dose did not affect the response
rate; there were 3 CR, 10 PR, 4 SD and 6 PD among the 23
evaluable patients on the 7 day CLB regimen. Although
patient numbers are small, Table IV suggests that the
incidence of complete remission may be highest in patients
with minimal residual disease initially.
Survival
Median survival of the 45 patients with epithelial ovarian
cancer was 15 months. Patients achieving CR received no
further treatment; one relapsed within 6 months of laparo-
tomy, the others are disease free with a median follow-up of
15 months. Patients with a partial response were given 3
further courses of carboplatin and CLB; their median survi-
val was 16 months. Further treatment of patients with stable
or progressive disease was at the discretion of the responsible
consultant; median survivals were 10 and 5 months
respectively.
All 3 patients with no residual disease prior to chemo-
therapy are clinically disease free. The median survival of
patients with minimal residual disease was 16 months, and
13 months for those with moderate or bulk tumour.
Discussion
This study has demonstrated that repeated courses of a
carboplatin and CLB combination may be safely admini-
stered to patients with ovarian cancer. Myelosuppression was
variable and, although the CLB dosage may have determined
the duration of leucopenia in initial treatment cycles, it did
not correlate with nadir blood counts. The dose limiting
toxicity of the combination in the initial phase of the study
was day 42 grade I leucopenia, but the later phase showed
that patients can be retreated at this level without serious
toxicity. Our experience suggests that the appropriate CLB
dose will be 70mg per cycle for most patients.
The maximal tolerated carboplatin dosage, in combination
with 70mg per cycle CLB, varied apparently independently
of creatinine clearance. EDTA clearance may provide a more
accurate assessment of renal function and carboplatin excre-
tion; it has been shown to correlate with myelosuppression
in pretreated patients (Calvert et al., 1982). In a similar
patient population with small cell lung cancer, carboplatin
300mgm2 in combination with VP16-213 resulted in com-
parable myelotoxicity to the regimen used in this study
(Smith et al., 1987). Our data indicate that 300mgm2 is an
appropriate initial dose for patients with ovarian cancer;
although a minority will require subsequent dose reduction,
dose escalation may be possible.
The 57% response rate is at the lower end of the reported
range for platinum-based combination chemotherapy (Sessa,
1986). It is not clear whether this was in part attributable to
suboptimal drug doses, as patient numbers were too low for
multivariate analysis. However, there is a correlation
between response and extent of residual disease after initial
surgery (Gruppo Internationale Cooperativo Oncologico
Ginecologia, 1987) and patients with minimal or no residual
disease comprised a minority of our patient population (11/
37 evaluable). The proportion of tumours progressing on
chemotherapy was high (10/37); of these 8 had residual
disease greater than 2cm at the start of treatment.
The combination was generally well tolerated despite
relatively frequent nausea or vomiting. The majority of
patients without progressive disease had a Karnofsky Perfor-
mance status of 100. This represented significant improve-
ment over our prior experience with a cisplatin (50mgm 2
per cycle) containing combination during which prolonged
malaise and lethargy were common.
This study confirmed the feasibility and relative non-
toxicity of carboplatin and CLB at doses which result in an
acceptable response rate. It remains to be seen in the
randomised trial whether this combination has any advan-
tage over single agent carboplatin at optimal dose.
We are grateful to Bristol Myers for supplies of carboplatin, the
Cancer Research Campaign for support of the Clinical Trials Unit
and Liz Sharkie for typing the manuscript.
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